ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
China National Drug Administration grants rapid approval of Roche's Alecensa (alectinib) as a treatment for ALK-positive lung cancer
August 24, 2018Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the China National Drug Administration (CNDA) has granted marketing authorisation for Alecensa® (alectinib) as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced -
China National Drug Administration grants rapid approval of Roche's Alecensa (alectinib) as a treatment for ALK-positive lung cancer
August 23, 2018Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the China National Drug Administration (CNDA) has granted marketing authorisation for Alecensa® (alectinib) as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced
Pharma Sources Insight January 2025
